BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:T3011 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of T3011\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06214143-2069@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:T3011: Phase 1/2 readout est. (NCT06214143)
DESCRIPTION:T3011\, phase 1/2.\nStudy: A Clinical Study of T3011 in Combina
 tion With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/t3011#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06214143
URL:https://assetmemo.bio/drug/t3011#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971614-2069@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:T3011: Phase 2 readout est. (NCT06971614)
DESCRIPTION:T3011\, phase 2.\nStudy: A Study of T3011 in Patients With BCG-
 Unresponsive NMIBC or BCG-Exposed\, Chemotherapy-Unresponsive NMIBC\nEstim
 ated primary completion: 31 December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/t3011#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06971614
URL:https://assetmemo.bio/drug/t3011#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
